US 12,281,176 B2
Binding molecules for BCMA and CD3
Peter Kufer, Munich (DE); Tobias Raum, Munich (DE); Patrick Hoffmann, Munich (DE); Roman Kischel, Munich (DE); Ralf Lutterbuese, Munich (DE); Doris Rau, Munich (DE); Paul Adam, Munich (DE); Eric Borges, Munich (DE); Barbara Hebeis, Munich (DE); and Susanne Hipp, Munich (DE)
Assigned to Amgen Inc., Thousand Oaks, CA (US); and Amgen Research (Munich) GmbH, Munich (DE)
Filed by Amgen Inc., Thousand Oaks, CA (US); and Amgen Research (Munich) GmbH, Munich (DE)
Filed on Jun. 1, 2021, as Appl. No. 17/336,152.
Application 17/336,152 is a continuation of application No. 17/011,849, filed on Sep. 3, 2020.
Application 17/011,849 is a continuation of application No. 14/358,511, granted, now 10,766,969, previously published as PCT/EP2012/072699, filed on Nov. 15, 2012.
Claims priority of provisional application 61/651,486, filed on May 24, 2012.
Claims priority of provisional application 61/651,474, filed on May 24, 2012.
Claims priority of provisional application 61/560,183, filed on Nov. 15, 2011.
Claims priority of provisional application 61/560,162, filed on Nov. 15, 2011.
Claims priority of provisional application 61/560,149, filed on Nov. 15, 2011.
Claims priority of provisional application 61/560,144, filed on Nov. 15, 2011.
Claims priority of provisional application 61/560,178, filed on Nov. 15, 2011.
Prior Publication US 2022/0356268 A1, Nov. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/46 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/468 (2013.01) [A61K 39/0005 (2013.01); C07K 14/70578 (2013.01); C07K 16/2809 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); A61K 2039/575 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01); C07K 2319/43 (2013.01)] 7 Claims
 
1. An antibody comprising:
a binding domain that binds to human CD3; and
further a polypeptide comprising the amino acid sequence of SEQ ID NO: 737 with 0, 1, 2, 3, 4, 5, or 6 amino acid substitutions and 0, 1, or 2 amino acid insertions or deletions to SEQ ID NOs: 731, 732 and/or 733 contained within SEQ ID NO: 737, and
0, 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid substitutions and 0, 1, 2, 3 or 4 amino acid insertions or deletions to the remainder of SEQ ID NO: 737.